

July 30, 2010

sanofi-aventis K.K.
Mitsubishi Tanabe Pharma Corporation

Press Release

Selective β_1 Receptor Blocker "KERLONG® Tablets 5mg/10mg" Transfer of Manufacturing, Marketing, and Distribution Rights

Sanofi-aventis K.K. (Head office: Shinjuku-ku, Tokyo; President & CEO: Patrick Chocat, hereinafter: saKK) and Mitsubishi Tanabe Pharma Corporation (Head office: Osaka City, Osaka; President & CEO: Michihiro Tsuchiya, hereinafter: Mitsubishi Tanabe) have signed an agreement regarding the transfer of manufacturing and marketing rights of the selective β_1 receptor blocker "KERLONG® 5mg/10mg (generic name: betaxolol hydrochloride)" from Mitsubishi Tanabe to saKK as of October 1, 2010.

Accordingly, as the new manufacturer / distributor of KERLONG®, saKK will ensure the promotion and distribution from October 1, 2010 onward.

KERLONG® is a compound first created by sanofi-aventis (France). Mitsubishi Tanabe obtained manufacturing right in October 1992, as an agent to treat essential hypertension (mild to moderate), renal parenchymal hypertension, and angina pectoris, and started sales in January 1993.

Contacts: sanofi-aventis K.K.
Communications
TEL: 03-6301-4148

Mitsubishi Tanabe Pharma Corporation
Corporate Communications Department
TEL: 06-6205-5211